Trial Profile

A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RSIFN-co (Primary)
Indications Carcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Neuroendocrine carcinoma; Prostate cancer; Renal cancer; Solid tumours
Focus Adverse reactions
Acronyms EffTox
Sponsors Sichuan Huiyang Life Science and Technology Corporation

Most Recent Events

25 Feb 2025 Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.
25 Feb 2025 Status changed from active, no longer recruiting to discontinued.
16 Apr 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com